Drug Profile
Research programme: NC1 inhibitors - BioStratum
Alternative Names: NC1 inhibitors research programme - BioStratumLatest Information Update: 28 Jan 2011
Price :
$50
*
At a glance
- Originator BioStratum
- Class
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Jan 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 06 Apr 2004 This programme is available for licensing (http://www.biostratum.com)
- 18 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)